公开(公告)号：NZ736048A

公开(公告)日：2019-09-27

申请号：NZ73604811

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID ,  HEDRICK ERIC ,  ELIAS LAURENCE ,  MODY TARAK ,  FYFE GWEN ,  BUGGY JOSEPH

IPC: A61K31/519 ,  A61K31/4162 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

Abstract: Described is the use of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (ibrutinib / PCI-32765) in the manufacture of a medicament for treating relapsed or refractory follicular lymphoma in an individual in need thereof, wherein the medicament is formulated for administration of the compound once per day in an amount of about 560 mg, in a solid oral dosage form.

公开(公告)号：CA3113343A1

公开(公告)日：2011-12-08

申请号：CA3113343

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID ,  MODY TARAK

IPC: A61K31/519 ,  A61P35/00

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：CA3143428A1

公开(公告)日：2008-10-09

申请号：CA3143428

申请日：2008-03-27

Applicant: PHARMACYCLICS LLC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  BUGGY JOSEPH J ,  LOURY DAVID ,  CHEN WEI

Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.

公开(公告)号：SG10201809111XA

公开(公告)日：2018-11-29

申请号：SG10201809111X

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID ,  MODY TARAK

Abstract: THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. Fig. 1

公开(公告)号：CA3001152A1

公开(公告)日：2008-10-09

申请号：CA3001152

申请日：2008-03-27

Applicant: PHARMACYCLICS LLC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  BUGGY JOSEPH J ,  LOURY DAVID ,  CHEN WEI

IPC: C07D487/04 ,  A61K31/519 ,  A61K47/54 ,  A61P35/00 ,  A61P37/06 ,  G01N33/483 ,  G01N33/573

Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.

公开(公告)号：MA38961A1

公开(公告)日：2018-05-31

申请号：MA38961

申请日：2014-09-29

Applicant: PHARMACYCLICS LLC

Inventor： CHEN WEI ,  LOURY DAVID ,  WANG LONGCHENG ,  JIA ZHAOZHONG

IPC: A61K31/519 ,  A61P19/00 ,  A61P19/02 ,  C07D401/14 ,  C07D403/14

Abstract: La présente invention concerne des composés qui forment des liaisons covalentes avec la tyrosine kinase de bruton (btk). L'invention concerne également des inhibiteurs irréversibles de btk. De plus, des inhibiteurs réversibles de btk sont également décrits. L'invention concerne également des compositions pharmaceutiques qui comprennent les composés. L'invention concerne de plus des procédés d'utilisation des inhibiteurs de btk, seuls ou en combinaison avec d'autres agents thérapeutiques, pour le traitement de maladies ou d'états auto-immuns, de maladies ou d'états hétéro-immuns, du cancer, comprenant un lymphome, et de maladies ou d'états inflammatoires.

公开(公告)号：NZ772688A

公开(公告)日：2022-09-30

申请号：NZ77268811

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID ,  MODY TARAK

IPC: A61K31/519 ,  A61K31/4162 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

Abstract: Use of ibrutinib as an irreversible inhibitor of Bruton’s tyrosine kinase (BTK), in the manufacture of a medicament for treating chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), wherein said medicament is to be administered in an oral dose of 420 mg of said inhibitor once per day until progression of the CLL or SLL or unacceptable toxicity; and lymphocytosis is not considered progression of the CLL or SLL.

公开(公告)号：NZ755485A

公开(公告)日：2021-04-30

申请号：NZ75548511

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID ,  HEDRICK ERIC ,  ELIAS LAURENCE ,  MODY TARAK ,  FYFE GWEN ,  BUGGY JOSEPH

IPC: A61K31/519 ,  A61K31/4162 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

Abstract: Use of ibrutinib in the manufacture of a medicament for treating multiple myeloma (MM) in an individual in need thereof, wherein the medicament is formulated for administration at an ibrutinib dosage of about 420 to about 840 mg once per day in a solid oral dosage form. Preferably the medicament is in the form of capsules containing a once per day dosage of 420 mg, 560 mg or 840 mg.

公开(公告)号：AU2013245503B2

公开(公告)日：2015-09-24

申请号：AU2013245503

申请日：2013-10-17

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID ,  VERNER ERIK ,  CHEN WEI ,  HONIGBERG LEE ,  BUGGY JOSEPH

IPC: A61K31/52 ,  A61P35/00

Abstract: Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.

公开(公告)号：AU2008232762B2

公开(公告)日：2013-09-19

申请号：AU2008232762

申请日：2008-03-27

Applicant: PHARMACYCLICS LLC

Inventor： VERNER ERIK ,  LOURY DAVID ,  HONIGBERG LEE ,  CHEN WEI ,  BUGGY JOSEPH J

IPC: C07D253/06 ,  A61K31/519 ,  A61K31/52 ,  A61P29/00 ,  A61P35/00 ,  C07D473/34 ,  C07D487/04

Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.